Merrill Lynch analyst Geoff Meacham reiterated a Buy rating on Biocryst Pharmaceuticals on Monday, setting a price target of $9, which is approximately 24.65% above the present share price of $7.22.
Meacham expects Biocryst Pharmaceuticals to post earnings per share (EPS) of -$0.26 for the fourth quarter of 2020.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in BioCryst (NASDAQ:BCRX), with an average price target of $9.36.
The analysts price targets range from a high of $14 to a low of $4.5.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $6.1 million and a net profit of -$42.86 million. The company's market cap is $1.08 billion.
According to TipRanks.com, Merrill Lynch analyst Geoff Meacham is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.2% and a 55.69% success rate.
BioCryst Pharmaceuticals , Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.